Device will be used in several upcoming clinical studies.
Swiss pharma also aims for new CAR-T therapy indication.
Each Trust will receive £70 million to develop digital technologies.
Patients suffering from a recurrent C diff infection have benefited from Rebiotix’s microbiome treatment.
Deal with MRCT will look for potential new drug targets and candidates.